文献速递造血干细胞移植与细胞治疗

缺氧预处理的小型间充质干细胞减轻移植物抗宿主病

Small hypoxia-primed mesenchymal stem cells attenuate graft-versus-host disease.
PubMed 文献 · Leukemia · 2018-05-22

研究比较缺氧与钙离子预处理的小型间充质干细胞(SHC-MSCs)与常规培养人脐带血来源MSCs,发现SHC-MSCs抗衰老、分泌促血管生成和免疫调节因子并抑制T细胞增殖。在人源化小鼠模型中,输注SHC-MSCs或过表达PLK1的MSCs显著改善GVHD症状、提高生存率、减少体重丢失并减轻靶器官病理损伤。

要点

  • SHC-MSCs通过MCP-1及p53/p21通路抵抗传代衰老,并大量分泌促血管生成与免疫调节因子。
  • SHC-MSCs在多能性、生殖系和印记基因上呈DNA去甲基化,类似极小胚胎样干细胞。
  • 人源化小鼠中输注SHC-MSCs或过表达PLK1的MSCs较输注常规MSCs显著改善GVHD生存与病理。

核心结论

  • SHC-MSCs可改善包括GVHD在内的同种异体冲突的临床治疗。

研究设计与样本

  • 研究比较缺氧与钙离子预处理的小型间充质干细胞(SHC-MSCs)与常规培养人脐带血来源MSCs,并在人源化小鼠模型中评估疗效。

主要发现

  • 与常规培养人脐带血来源MSCs相比,SHC-MSCs抵抗由单核细胞趋化蛋白-1及p53/p21级联介导的传代衰老,并大量分泌促血管生成和免疫调节因子,抑制T细胞增殖。
  • SHC-MSCs在多能性、生殖系和印记基因上呈DNA去甲基化,类似极小胚胎样干细胞,提示潜在相互关系。
  • 全基因组DNA甲基化组和转录组分析显示,SHC-MSCs中免疫调节、细胞黏附和细胞周期相关基因上调。
  • PLK1、锌指蛋白143、脱氢酶/还原酶3和friend-of-GATA2在SHC-MSCs的有益效应中起关键作用。
  • 人源化小鼠模型中,输注SHC-MSCs或过表达PLK1的MSCs较输注常规MSCs显著改善GVHD症状,显著提高生存率、减少体重丢失并减轻GVHD靶器官组织病理损伤。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mesenchymal stem cells (MSCs) are of particular interest for the treatment of immune-related diseases due to their immunosuppressive capacity. Here, we show that Small MSCs primed with Hypoxia and Calcium ions (SHC-MSCs) exhibit enhanced stemness and immunomodulatory functions for treating allogeneic conflicts. Compared with naïve cultured human umbilical cord blood-derived MSCs, SHC-MSCs were resistant to passage-dependent senescence mediated via the monocyte chemoattractant protein-1 and p53/p21 cascade and secreted large amounts of pro-angiogenic and immunomodulatory factors, resulting in suppression of T-cell proliferation. SHC-MSCs showed DNA demethylation in pluripotency, germline, and imprinted genes similarly to very small embryonic-like stem cells, suggesting a potential mutual relationship. Genome-wide DNA methylome and transcriptome analyses indicated that genes related to immune modulation, cell adhesion, and the cell cycle were up-regulated in SHC-MSCs. Particularly, polo-like kinase-1 (PLK1), zinc-finger protein-143, dehydrogenase/reductase-3, and friend-of-GATA2 play a key role in the beneficial effects of SHC-MSCs. Administration of SHC-MSCs or PLK1-overexpressing MSCs significantly ameliorated symptoms of graft-versus-host disease (GVHD) in a humanized mouse model, resulting in significantly improved survival, less weight loss, and reduced histopathologic injuries in GVHD target organs compared with naïve MSC-infused mice. Collectively, our findings suggest that SHC-MSCs can improve the clinical treatment of allogeneic conflicts, including GVHD.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kim Y, Jin HJ, Heo J, et al. Small hypoxia-primed mesenchymal stem cells attenuate graft-versus-host disease. Leukemia. 2018. PMID: 29789652. doi:10.1038/s41375-018-0151-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。